[ RECIPIENT ENTITY RECORD ]

AbbVie ImmunoGen Platform

VERIFIED NODE ID: 002115 · abbvie-immunogen-platform
R TARGET NODE — CAPITAL RECIPIENT
AbbVie ImmunoGen Platform
SPV United States
Recipient Type
SPV
Primary Jurisdiction
United States
Registration Status
ACTIVE
Entity Intelligence [ R ]
Legal Name AbbVie ImmunoGen Platform
Entity Type SPV
Jurisdiction United States
Recipient Intelligence Summary

AbbVie ImmunoGen Platform represents the leading biotechnology division focused on developing targeted antibody-drug conjugates for cancer treatment. The project provides commercially available therapies for oncology. It was the destination for a significant institutional healthcare investment in targeted medicine.

Capital Influx Log (Transactions)
Date Type Amount
23 May 2026 EQUITY $10.1B